Table 3.
Survival data.
| Study | Median follow-up, months | Median OS, months (95%CI) | Median DFS, months (95%CI) |
1y OS (95%CI) |
1y DFS (95%CI) |
2y OS (95%CI) |
2y DFS (95%CI) |
|---|---|---|---|---|---|---|---|
| Cowzer, D., et al. (19) | 30 | NA | NA | 92% (83%-100%) | 81% (69%-95%) | 85% (74%-98%) | 71% (58%-88%) |
| Kelly, R. J., et al (32), | 30 | NA | 35.4 (24.7-NA) |
NA | 79.1% (65.5-95.6%) | NA | NA |
| Lee, S., et al. (33) | NA | NA | NA | 80.80% | NA | 73.10% | NA |
| Uboha, NV., et al. (25) | 9.8 | NA | NA | 77% | 67% | NA | NA |
| van den Ende, T., et al. (13) | 24 | 29.7 | 19.4 | NA | NA | NA | NA |
| Yang, P., et al. (48) | NA | NA | NA | 90.90% | 83% | NA | NA |
OS, overall survival; DFS, disease-free survival; NA, not available.